Kali Inc Enters Discussions with Puration and Nouveau Life Pharmaceuticals to Enter $50 Billion Cannabis Pharmaceuticals Market
October 29 2018 - 10:13AM
InvestorsHub NewsWire
Kali Inc Enters Discussions with
Puration and Nouveau Life Pharmaceuticals to Enter $50 Billion
Cannabis Pharmaceuticals Market
Sarasota, FL -- October 29, 2018 --
InvestorsHub NewsWire -- Kali, Inc. (USOTC:
KALY) today announced entering into discussions with Puration,
Inc. (USOTC:
PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC:
NOUV) to explore forming a joint venture company between the
three to develop cannabis pharmaceutical products. Kali
recently announced a letter of intent to acquire NCM Biotech, the
developer and owner of a patented cannabis extraction process -
U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR
PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS
PLANT.” Separately, Puration has licensed the NCM patent for
use in specific commercial applications. Nouveau has recently
acquired a cannabis cultivation operation from Puration. In the
joint venture, Kali would build on NCM’s medical research, and
Puration’s commercial experience, combined with Nouveau’s plans to
develop a proprietary pharmaceutical grade hemp cultivar, to
together develop cannabis pharmaceutical products in partnerships
with established pharmaceutical development
companies.
Frederick Ferri, CEO and Founder of
NCM Biotech notes, “Some feedback has specifically indicated that a
number of our candidate pharmaceutical products under development
have a greater efficacy potential than GW
Pharmaceutical [GWPH]
products and candidate products.“
NCM
Biotech’s medical advisory team includes John N.
Gaitanis, MD., Director of Child Neurology at Tufts Medical
Center/Floating Hospital for Children; Lloyd R. Saberski,
M.D., Associate Professor of Anesthesiology and Chronic Pain
Management, Yale University, and John McMichael, Ph.D., President
& CEO Beech Tree Labs.
Learn more about NCM Biotech at
https://www.ncmbiotech.com/
Look for more info on the Kali’s
plans with NCM biotech and Puration and Nouveau later this week in
a management presentation on the company’s comprehensive post
acquisition business plan.
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Kali, Inc.
941.444.6994
management@wavemarineservices.com
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From May 2024 to Jun 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Jun 2023 to Jun 2024